Company: ERAS
Filing Date: 2025-03-20
Form Type: 10-K
Source: 0000950170-25-042682
Chunk: 51

Company: Erasca, Inc.
Filing Date: 2025-03-20
Form: 10-K
Item: Item 1
Chunk 51
---
2024, we have in-licensed ten patent families from Novartis. The ten patent families relate to RAF inhibitors, their preparation, and methods of use. One of the families covers the naporafenib product candidate compound and additional RAF inhibitor compounds, their preparation and methods of use, and includes four issued US patents, eighty-six issued foreign patents, and five pending foreign patent applications. The nine additional in-licensed families cover further methods of using naporafenib, diagnostic methods, and additional RAF inhibitor compounds, their preparation and methods of use, and include six issued US patents, seven pending US non-provisional applications, one pending PCT patent application, fifty issued foreign patents, and forty-nine pending foreign patent applications. The granted patents and any further patents that issue from applications from the ten in-licensed families are expected to expire between 2034 and 2043, absent any patent term adjustments or extensions.

As of December 31, 2024, we own two patent families relating to naporafenib and their methods of use and include two pending PCT patent applications and two pending foreign patent applications. Any patents issued from these patent applications are expected to expire in 2044, absent any patent term adjustments or extensions.

38

ERAS-0015

As of December 31, 2024, we have in-licensed one patent family from Joyo. The patent family relates to compositions of RAS molecular glues, their preparation and methods of use, and includes one pending foreign patent application and one pending PCT patent application. Any patents that issue from applications for the in-licensed family are expected to expire in 2043, absent any patent term adjustments or extensions.

As of December 31, 2024, we own six patent families relating to methods of using ERAS-0015 and include six pending US provisional applications. Any patents issued from these applications are expected to expire in 2045, absent any patent term adjustments or extensions.

ERAS-4001

As of December 31, 2024, we have in-licensed one patent family from Medshine relating to RAS inhibitors, their preparation, and methods of use. The patent family includes one pending US non-provisional patent application, seven pending foreign patent applications, and one pending PCT patent application. Any patents that issue from applications for the in-licensed family are expected to expire in 2043, absent any patent term adjustments or extensions.

As of December 31, 2024, we own